Loading
A phase 3 trial testing SHR-A2009 in non-small-cell lung cancer, active and no longer recruiting.
A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC is a phase 3 interventional study registered as NCT06671379, led by Suzhou Suncadia Biopharmaceuticals, and active but no longer recruiting on the registry. Official title: A Randomised, Open-label, Multicenter, Phase III Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy. Planned enrolment is 498 participants (actual). The study started in 2024-11-29 and primary completion is expected in 2026-12. No results have been posted on ClinicalTrials.gov.
Shares SHR-A2009, Jiangsu Hengrui Pharmaceuticals, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.
Shares SHR-A2009, Jiangsu Hengrui Pharmaceuticals.
Shares Jiangsu Hengrui Pharmaceuticals, Non-small-cell lung cancer.
Shares SHR-A2009, Jiangsu Hengrui Pharmaceuticals.
Shares Jiangsu Hengrui Pharmaceuticals, Non-small-cell lung cancer.
Shares Jiangsu Hengrui Pharmaceuticals, Non-small-cell lung cancer.
Shares Jiangsu Hengrui Pharmaceuticals, Non-small-cell lung cancer.
Shares Jiangsu Hengrui Pharmaceuticals, Non-small-cell lung cancer.